Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: -1.60 (-1.31%)
Spread: 0.40 (0.333%)
Open: 120.20
High: 121.60
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Stocks set lower after US Fed decision, ahead of ECB

Thu, 15th Jun 2023 07:55

(Alliance News) - Stocks in London were set to open lower on Thursday, after the US Federal Reserve paused its interest rate hikes but indicated that more will follow this year.

The US central bank left the federal funds rate range unchanged at a range of 5.00% to 5.25%.

Speaking to reporters after the decision, Fed Chair Jerome Powell said nearly all committee participants view some further hikes this year as "appropriate".

Chris Beauchamp, chief market analyst at IG, said "any lingering hope" of a rate cut this year from the Fed now seems to have gone following this meeting.

In the wake of the announcement, Wall Street ended mixed, but the dollar was stronger.

With the Fed decision made, the European Central Bank is up next. The ECB will announce its interest rate decision on Thursday at 1315 BST. A press conference with President Christine Lagarde will follow half an hour later.

In contrast to the US central bank, another 25 basis point hike by the ECB is see as a done deal by markets.

In early UK corporate news, distribution services firm Halma boasted a record annual revenue figure but lower profit. Online fashion retailer Asos said it had "restored profitability".

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 17.34 points, or 0.2%, at 7,585.40

----------

Hang Seng: up 1.6% at 19,715.34

Nikkei 225: closed down 0.1% at 33,485.49

S&P/ASX 200: closed up 0.2% at 7,175.30

----------

DJIA: closed down 232.79 points, or 0.7%, at 33,979.33

S&P 500: closed up 0.1% at 4,372.59

Nasdaq Composite: closed up 0.4% at 13,626.48

----------

EUR: lower at USD1.0818 (USD1.0850)

GBP: lower at USD1.2651 (USD1.2694)

USD: higher at JPY141.30 (JPY139.37)

Gold: lower at USD1,935.49 per ounce (USD1,957.97)

(Brent): lower at USD73.52 a barrel (USD74.27)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

UK BoE Deputy Governor Jon Cunliffe speaks at Politico Global Tech summit

11:00 CEST EU foreign trade

14:15 CEST EU interest rate announcement

08:30 EDT US import and export price index

08:30 EDT US Philadelphia Fed business outlook survey

08:30 EDT US unemployment insurance weekly claims report

09:15 EDT US industrial production

16:30 EDT US foreign central bank holdings

16:30 EDT US federal discount window borrowings

----------

China reported a series of weak economic indicators, with youth unemployment hitting a record high for the second consecutive month as the economy's post-Covid growth spurt fades. The unemployment rate for Chinese between the ages of 16 and 24 rose to 20.8%, up from what was already a record 20.4% in April, the National Bureau of Statistics said. Overall urban unemployment remained at 5.2%, the NBS said in a statement. Meanwhile, industrial production rose 3.5% in May, down from 5.6% a month earlier, as factories gradually returned to full capacity. Retail sales, the main indicator of household consumption, rose by 12.7% on-year compared with 18.4% a month earlier.

----------

Amid the weak economic readings, China's central bank cut a key interest rate and injected USD33 billion into financial market. The medium-term lending facility rate – the interest for one-year loans to financial institutions – was lowered 10 basis points to 2.65%, the People's Bank of China said in a statement. The PBOC also said it was offering USD33 billion of funds to banks through the medium-term lending facility, "to maintain reasonable and sufficient liquidity in the banking system". The bank also announced a surprise cut in a short-term interest rate this week, which analysts said reflected growing concern about the state of the economy among Chinese policymakers.

----------

A strike by junior doctors in England will continue on Thursday as new figures showed that more than half a million appointments and procedures have been postponed due to industrial action since December. Members of the British Medical Association will mount picket lines outside hospitals across the country for the second of a three-day walkout in a long-running row over pay. The action is expected to lead to tens of thousands more appointments and procedures being delayed. The dispute remains deadlocked, with no talks planned amid a standoff between the BMA and government. The BMA has urged Prime Minister Rishi Sunak to get involved in talks, but it was made clear he is not going to intervene.

----------

BROKER RATING CHANGES

----------

Goldman Sachs cuts Diageo to 'neutral' (buy) - price target 3,700 (4,500) pence

----------

Berstein starts AB Foods with 'outperform'

----------

Berenberg starts Adriatic Metals with 'buy' - price target 280 pence

----------

COMPANIES - FTSE 100

----------

Bunzl said it expects to deliver another "resilient" performance in the first half of 2023, with revenue expected to be up between 4% and 5% year-on-year at actual exchange rates, or 1% at constant exchange rates. The distribution services company said that, in 2023 as whole, revenue is expected to be "slightly" higher than in 2022. Bunzl also announced it has entered an agreement to acquire EHM, a distributor of personal protective equipment products in the UK. The company said the acquisition would be complementary to its existing safety business. The financial details were not disclosed.

----------

Halma boasted a record annual revenue figure in the financial year that ended March 31 but lower profit. The safety equipment manufacturer posted pretax profit of GBP291.5 million, down from GBP304.4 million the year prior. Halma said the drop in profitability reflected the non-recurrence of a GBP34.0 million gain on a disposal in the year prior. Excluding this gain, pretax profit was up 8% year-on-year, it said. Revenue from continuing operations totalled GBP1.85 billion, up from GBP1.53 billion. Chief Executive Marc Ronchetti said: "We have made a positive start to the new financial year. We have a strong order book, and order intake in the year to date is broadly in line with revenue and ahead of the comparable period last year. Based on current market conditions, we expect to deliver good organic constant currency revenue growth in the year ahead, and return on sales to increase to approximately 20%."

----------

COMPANIES - FTSE 250

----------

Asos said it returned to profitability with its 'P3' adjusted earnings before interest and tax in the three months ended May 31, despite a drop in revenue. P3 adjusted Ebit was improved by more than GBP20 million year-on-year, putting the online fashion retailer on-track to deliver adjusted Ebit guidance of GBP40 million to GBP60 million in the second half of its financial year. Revenue fell 14% year-on-year, as expected by the company. Chief Executive Jose Antonio Ramos Calamonte said: "I am confident in the direction we are going, we have restored profitability in the period and made good progress in clearing through our inventory to generate cash. We retain ample balance sheet flexibility and reiterate our expectations for improved profitability, cash generation and reduction in net debt in H2 FY23 and beyond."

----------

Syncona reported a lower net asset value per share at the end of March amid a "challenging" backdrop for the biotechnology companies. The healthcare investor reported a net asset value per share of 186.5 pence as at March 31, down from 194.4p at the same time a year prior. Its total NAV return in the financial year that ended March 31 was negative 4.1%, compared to positive 0.3% the year prior. The company's life science portfolio is valued at GBP604.6 million as of March 31. Syncona said its performance had been driven by the continued share price declines of its listed holdings, which it said partially reflected the wider market backdrop for biotech companies and the write down of its valuation of SwanBio. Syncona has written down its holding in SwanBio to GBP58.2 million, a GBP51.0 million decline in value during the year.

----------

OTHER COMPANIES

----------

Kew Soda, also known as WE Soda, late Wednesday cancelled plans to float on the London Stock Exchange, with the soda ash producer explaining that UK investors are cautious about the initial public offering market. Chief Executive Alasdair Warren said: "Since our intention to float announcement some weeks ago, we had been encouraged by the breadth of investor engagement globally and the subsequent interest from prospective investors in our IPO. "Despite this, the reality is that investors, particularly in the UK, remain extremely cautious about the IPO market and this extreme investor caution in London meant that we were unable to arrive at a valuation that we believe reflects our unique financial and operating characteristics." WE Soda is the world's largest natural soda ash producer. It is based in London with production facilities in Turkey.

----------

GB Group said it was hurt by "unexpectedly deep post-pandemic corrections" in some of its end markets in the financial year that ended March 31, as it swung to an annual loss. The digital location and identity services provider explained that the corrections were largely felt in the internet economy, notably by cryptocurrency and fintech customers in its Identity business in the Americas. GB Group reported a loss of GBP119.8 million, swinging from a profit of GBP15.3 million the year prior. Revenue totalled GBP278.8 million, up from GBP242.5 million. Chief Executive Chris Clark said: "Looking ahead to FY24, since our update in February, there has been no material change in market conditions. Uncertainty remains; however, we still expect some gradual revenue acceleration in the latter part of the year. The board is confident that GBG will deliver its FY24 profit expectations assisted by a group-wide focus on efficiency. "

----------

Origin Enterprises said its markets in the nine months ended April 30 have been "significant" price and volume volatility, requiring "close management". The agronomy services firm said revenue in the period was up 9.3% against the year prior at EUR1.92 billion despite third quarter revenue falling 16% year-on-year. It explained that its performance in the third quarter quarter of its financial year was impacted by cautious on farm sentiment and poor northern hemisphere in-field conditions delaying key crop input applications. However, Origin noted that weather conditions and demand have improved into its fourth quarter. It expects adjusted diluted earnings per share for the full-year between 50.0 euro cents to 53.0 cents.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.